Skip to content
Trial Eligibility
Menu

A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors

NCT07945821

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Solid Tumor

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1/2
Ages
18 years and older
Sex
Male
Healthy volunteers
Not accepted
Sponsor
Coherus Oncology, Inc.
Last updated on ClinicalTrials.gov
November 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Washington · 1

  • Fred Hutchinson Cancer Center · Seattle, WA

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.